WO2017215677A3 - Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie - Google Patents
Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie Download PDFInfo
- Publication number
- WO2017215677A3 WO2017215677A3 PCT/CN2017/097014 CN2017097014W WO2017215677A3 WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3 CN 2017097014 W CN2017097014 W CN 2017097014W WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbocisteine
- pharmaceutical composition
- effects
- treating leukemia
- leukemia
- Prior art date
Links
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 title abstract 6
- 229960004399 carbocisteine Drugs 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000032839 leukemia Diseases 0.000 title abstract 3
- 241001116757 Pyrrosia lingua Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610412276.XA CN106074561A (zh) | 2016-06-13 | 2016-06-13 | 羧甲司坦的药物组合物及其对白血病的治疗作用 |
CN201610412276.X | 2016-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017215677A2 WO2017215677A2 (fr) | 2017-12-21 |
WO2017215677A3 true WO2017215677A3 (fr) | 2018-02-15 |
Family
ID=57846453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/097014 WO2017215677A2 (fr) | 2016-06-13 | 2017-08-11 | Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106074561A (fr) |
WO (1) | WO2017215677A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105837422A (zh) * | 2016-04-20 | 2016-08-10 | 宋晓梅 | 一种盐酸丁丙诺啡的药物组合物及其在生物医药中的应用 |
CN106074561A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 羧甲司坦的药物组合物及其对白血病的治疗作用 |
CN106045835A (zh) * | 2016-06-23 | 2016-10-26 | 崔坤峰 | 盐酸苄丝肼的药物组合物及其降血糖的医药用途 |
CN106117166A (zh) * | 2016-06-23 | 2016-11-16 | 崔坤峰 | 氨力农的药物组合物及其在高血压治疗中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102805746A (zh) * | 2011-06-02 | 2012-12-05 | 湖南九典制药有限公司 | 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用 |
CN106074561A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 羧甲司坦的药物组合物及其对白血病的治疗作用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100584362C (zh) * | 2007-08-02 | 2010-01-27 | 徐平 | 一种治疗白血病的中药 |
-
2016
- 2016-06-13 CN CN201610412276.XA patent/CN106074561A/zh active Pending
-
2017
- 2017-08-11 WO PCT/CN2017/097014 patent/WO2017215677A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102805746A (zh) * | 2011-06-02 | 2012-12-05 | 湖南九典制药有限公司 | 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用 |
CN106074561A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 羧甲司坦的药物组合物及其对白血病的治疗作用 |
Non-Patent Citations (1)
Title |
---|
WANG YUANCHAO ET AL.: "Study on chemical constituents and pharmacological activities of Friedelane Triterpenes in Celastraceae", RESEARCH AND PRACTICE ON CHINESE MEDICINES, 31 December 2015 (2015-12-31), pages 73 - 79, ISSN: 1673-6427 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017215677A2 (fr) | 2017-12-21 |
CN106074561A (zh) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3433256T1 (sl) | Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka | |
WO2017215677A3 (fr) | Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie | |
ZA202103074B (en) | Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation | |
EP3398948A3 (fr) | Dérivés de ptéridine 2,4,6,7-tétrasubstituée et leurs procédés de synthèse et d'utilisation | |
WO2018013609A3 (fr) | Nanoparticules synthétiques de mélanine et leurs utilisations | |
WO2018023072A3 (fr) | Composés et compositions, et utilisations associées | |
WO2017136450A3 (fr) | Composés et méthodes de traitement de maladies médiées par l'arn | |
EP4339192A3 (fr) | Composés et compositions pour le traitement du cancer | |
WO2019204505A3 (fr) | Modulateurs de k-ras avec une fraction de sulfonamide de vinyle | |
WO2016149613A3 (fr) | Peptides de liaison à mcl-1 sélectifs | |
EP4327887A3 (fr) | Combinaisons et formulations à dose fixe comprenant etc1002 et une ou plusieurs statines et procédés de traitement ou de réduction du risque de maladie cardiovasculaire | |
EP3436049A4 (fr) | Protéine 8 de type angiopoïétine (angptl8) | |
WO2017220042A3 (fr) | Composition pharmaceutique d'amrinone et son application dans le traitement de l'hypertension | |
EP3572088A4 (fr) | Extrait de panax, composition pharmaceutique et utilisation | |
FR3044226B1 (fr) | Extrait alcoolique de parties aeriennes de solidago virgaurea subsp. alpestris, son procede d'obtention, et composition cosmetique ou dermatologique le contenant | |
WO2017215678A3 (fr) | Composition pharmaceutique de céfaclor et ses effets protecteurs contre les lésions pulmonaires aiguës | |
WO2016115054A3 (fr) | Modulateurs de canaux calciques ca2+ activés par la libération de calcium ca2+ (crac) et leurs utilisations pharmaceutiques | |
IL282999A (en) | 4,3,1-oxadiazolone compound and drug | |
EP3554496A4 (fr) | Procédés et compositions de traitement de la maladie de parkinson | |
PH12016501205A1 (en) | Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency | |
EP3441076A4 (fr) | Produit pharmaceutique destiné au traitement d'une tumeur et d'un défaut immunitaire combiné, préparation et application de ce dernier | |
EP3628008A4 (fr) | Compositions et méthodes pour le traitement de la maladie d'alzheimer | |
EP3616704A4 (fr) | Composition pharmaceutique destinée à la prévention ou au traitement de la maladie d'alzheimer, comprenant un extrait de ginseng cultivé en montagne | |
WO2018033742A3 (fr) | Composés | |
WO2017079403A3 (fr) | Nanoparticules polymères |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17812788 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17812788 Country of ref document: EP Kind code of ref document: A2 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04/07/2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17812788 Country of ref document: EP Kind code of ref document: A2 |